The percentages of active caspase-3-positive cells (apoptotic cells) in control and 80 mg/kg HSA/TIMP-2-treated groups were 10.2% and 10.8%, respectively, with no significant difference (Fig. 2B; P = 0.80 vs. control), suggesting no effect of HSA/TIMP-2 treatment on the apoptotic status of tumor cells. The gene discussed is CASP3; the disease is neoplasm.